News and Events
Extrachromosomal DNA promotes aggressiveness of small cell lung cancer
Cancers harboring small particles of DNA that exist outside of chromosomes, called extrachromosomal DNA (ecDNA), are associated with aggressive tumor growth, drug resistance, and shorter patient survival. New research shows that ecDNAs in small cell lung cancer contribute to variability between cancer cells, allowing them to rapidly evolve and leading to these undesirable outcomes.
Read More
Clinical trial studies a new form of vincristine in standard combination chemotherapy for children with relapsed ALL
A combination of chemotherapy drugs known by the regimen UK ALL R3 is one of the most successful treatments for patients with relapsed acute lymphoblastic leukemia (ALL). In this study, investigators hope to improve outcomes by combining the treatment with Marqibo, a new formulation of the drug vincristine. Learn more...
Read More
Center for Cancer Research plays key role in first FDA-approved drug for treatment of Merkel cell carcinoma
The Center for Cancer Research’s ability to rapidly deploy integrated basic and clinical research teams at a single site facilitated the rapid FDA approval of the immunotherapy drug avelumab for metastatic Merkel cell carcinoma, a rare, aggressive form of skin cancer. Learn more...
Read More
New clinical trial studies the use of avelumab in patients with recurrent thymoma and thymic carcinoma
A new study uses immunotherapy for patients whose thymoma or thymic carcinoma has progressed after standard treatments. Learn more...
Read More
Antibody-linked drug destroys tumor cells and tumor blood vessels in many types of cancer
A team led by Brad St. Croix, Ph.D., Senior Associate Scientist, Mouse Cancer Genetics Program, has developed an antibody-drug conjugate (ADC) that destroys both tumor cells and the blood vessels that nourish them. The drug significantly shrank breast tumors, colon tumors and several other types of cancer and prolonged survival. Learn more...
Read More
“They gave me my life back”
Collaboration between the CCR and NIAID helped a teenager eat a cheeseburger again. Learn more...
Read More
Foregut cancers get new attention at CCR
The newly formed NIH Foregut Team will focus on cancers of the esophagus, stomach, pancreas, liver, bile ducts and part of the small intestine. Although these tumors are not the most common types of cancers, they are among the deadliest. Learn more...
Read More
Novel target for high-risk neuroblastoma identified in pre-clinical research
Pre-clinical research by investigators at the Center for Cancer Research and their colleagues have identified a number of novel epigenetic targets for high-risk neuroblastoma and validated a promising new targeted inhibitor in pre-clinical models. Read more...
Read More